Biotech News

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

Pulmonx (LUNG)PulmonxConference / presentation

REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Canaccord Genuity 46 th Annual Growth

Related news

Pulmonx

Minimally Invasive COPD Treatment Pulmonx develops minimally invasive technologies for patients with severe emphysema and chronic obstructive pulmonary disease who remain highly symptomatic despite medical therapy. Zephyr Endobronchial Valve The Zephyr Valve is an implantable bronchoscopic device that occludes selected diseased lung...

Recent company news

Stock data

Close
2.05 USD
Market cap
68M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States